Genprex Recognizes World Cancer Day

Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide 

AUSTIN, Texas — (February 4, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today that it joins with millions of healthcare advocates around the world in support of World Cancer Day in order to raise awareness, elevate the public understanding of the global cancer burden, promote greater equity and ensure that cancer control continues to be a priority in the world health and development agenda.  

“At Genprex, our primary focus is on the patients and communities we serve. Toward that end, we are relentless in our pursuit to bring innovative and life-saving oncology treatments to patients suffering with cancers for which there are limited or no treatment options,” said Rodney Varner, Chief Executive Officer of Genprex. “This World Cancer Day, we extend great appreciation to our research colleagues around the world who are working to alleviate the global cancer burden and to the patients who graciously offer their support through participation in clinical trials in the hope of finding new and effective treatments, not only for themselves, but for those who come after them.” 

Genprex is reprogramming the course of cancer by developing gene therapies that have been designed and optimized to administer cancer-fighting genes. The Company’s lead product candidate, REQORSA™ immunogene therapy, may be administered in combination with approved therapies, such as targeted therapies and immunotherapies. Genprex holds an FDA Fast Track Designation for development of REQORSA™ in combination with EGFR inhibitor, Tagrisso® (marketed by AstraZeneca), in non-small cell lung cancer (NSCLC) patients whose disease progressed after treatment with Tagrisso. Genprex is advancing plans for its upcoming Acclaim-1 and Acclaim-2 clinical trials that combine REQORSA with Tagrisso® and with Keytruda® (marketed by Merck & Co., Inc.), respectively, for the treatment of NSCLC, both of which are on track to be initiated in the first-half of 2021.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone

For more information, please visit the Company’s web site at or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive necessary approvals to commence clinical trials or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]